The prospectus can be obtained from Enzymatica and Erik Penser Bank, and are available at Enzymatica’s web site (www.enzymatica.se) and at Erik Penser Bank’s web site (www.penser.se). Subscription forms will be available on Enzymatica’s and Erik Penser Bank’s web site from May 19, 2021 and throughout the subscription period.
Preliminary timetable for the rights issue
May 12, 2021 Last day of trading in the share including subscription rights
May 14, 2021 First day of trading in the share excluding subscription rights
May 17, 2021 Record date for participation in the rights issue
May 19- June 2, 2021 Subscription period
May 19-28, 2021 Trading in subscription rights
June 7, 2021 Estimated date of announcement of the outcome of the rights issue
Erik Penser Bank AB is Enzymatica’s financial adviser in connection with the rights issue. Mannheimer Swartling is the Company’s legal adviser.
For more information, please contact:
Bengt Baron, Executive Chairman, Enzymatica AB
Phone: +46 (0)708-59 30 09 | Email: firstname.lastname@example.org
Therese Filmersson, acting CEO and CFO, Enzymatica AB
Phone: +46 (0)708-40 72 24 | Email: email@example.com
Claus Egstrand, Chief Operating Officer & Senior Director Growth, Enzymatica AB
Phone: +44 7780 22 8385 | E-mail: firstname.lastname@example.org
Carl-Johan Wachtmeister, Communication manager, Enzymatica AB
Phone: +46 (0)701-88 50 21 | Email: email@example.com
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in Enzymatica. Any invitation to the persons concerned to subscribe for shares in Enzymatica will only be made through the prospectus that Enzymatica publishes today on May 12, 2021.
The information in this press release may not be released, published or distributed, directly or indirectly, in or into the United States (including its territories and provinces, every state in the United States and the District of Columbia), Australia, Hong Kong, Japan, Canada, New Zeeland, Switzerland, Singapore or South Africa or any other jurisdiction in which such action is subject to legal restrictions or would require other measures than those required by Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.
This press release does not contain or constitute an offer to acquire or subscribe to securities in the United States. No subscription rights, BTAs (interim shares) or shares have or will be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or the securities legislation of any state or other jurisdiction in the United States and may not be offered, subscribed, sold or otherwise transferred, directly or indirectly, in or within the United States, other than pursuant to an exemption from, or in a transaction that is not subject to, the registration requirements under the U.S. Securities Act and in accordance with the securities legislation in the relevant state or any other jurisdiction of the United States. Enzymatica does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering in the securities in the United States.
Within the European Economic Area (“EEA”), no public offering of securities is made in other countries than Sweden. In other member states of the EU, such an offering of securities may only be made in accordance with an applicable exemption in the Prospectus Regulation (EU) 2017/1129.
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily
conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases
Enzymatica’s certified adviser is Erik Penser Bank. Tel: +46 (0)8 463 83 00 E-mail: firstname.lastname@example.org